Maternal RSV Vaccine and Nirsevimab Sharply Cut Infant Hospitalizations, New Data Show

Maternal RSV vaccine and nirsevimab sharply cut infant hospitalizations, new data show

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction in RSV-associated hospitalizations among infants aged 0–7 months. The largest benefits were seen in the youngest and most vulnerable infants, particularly during peak winter months.

RSV wasn’t as hard on U.S. babies last winter. This may be why

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

RSV vaccines and nirsevimab tied to reduced RSV-linked hospitalization

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7 months during the 2024–2025 RSV season, the first season that the maternal vaccine and nirsevimab were widely available, according to research published in the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Early data show disparities in RSV vaccine uptake among pregnant patients

A new study presented at 2025 ACOG Annual Clinical and Scientific Meeting found disparities between RSV uptake in pregnant patients.

The lower incidence of RSV during the previous winter may have facilitated a smaller percentage of infant mortality in the United States

The RSV season during last winter was less severe for babies in the U.S., and a recent study suggests that using a maternal vaccine and a...

Considerations for RSV Vaccination During Pregnancy

Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.